LLY vs ABBV
By Alex · Tickerpine
Eli Lilly and Company vs AbbVie Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | ABBV |
|---|---|---|
| Price | $1,443.50 | $295.03 |
| Market cap | $1.29T | $521.50B |
| P/E ratio | 46.9 | 50.7 |
| ROE | 86.02% | — |
| Profit margin | 31.90% | 15.67% |
| Revenue growth | 38.60% | 10.30% |
| Dividend yield | 0.48% | 2.35% |
| Beta | 0.39 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs ABBV in plain English
- LLY is the bigger company — about 2.5× the market cap of ABBV.
- LLY is cheaper on earnings (P/E 46.9 vs 50.7).
- LLY is growing revenue faster (39% vs 10%).
- ABBV has the higher dividend yield (2.35% vs 0.48%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.